[{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"2cfcde7a-d491-42b2-9d06-8123de42c77d","acronym":"A091302","url":"https://clinicaltrials.gov/study/NCT02143726","created_at":"2021-09-08T20:53:26.218Z","updated_at":"2025-02-25T15:41:37.517Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT02143726 - A091302","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/09/2014","start_date":" 10/09/2014","primary_txt":" Primary completion: 01/28/2021","primary_completion_date":" 01/28/2021","study_txt":" Completion: 08/06/2028","study_completion_date":" 08/06/2028","last_update_posted":"2025-01-27"},{"id":"897d9629-7c12-4d49-92b0-10b4a3de5a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02973997","created_at":"2025-02-26T08:59:58.704Z","updated_at":"2025-02-26T08:59:58.704Z","phase":"Phase 2","brief_title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","source_id_and_acronym":"NCT02973997","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD8 • PD-L2","pipe":"","alterations":" ","tags":["CD8 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 10/08/2023","study_completion_date":" 10/08/2023","last_update_posted":"2024-07-01"},{"id":"ad64e5d0-95d3-4f41-a430-f89469610dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914300","created_at":"2023-12-06T21:16:15.541Z","updated_at":"2024-07-02T16:34:26.125Z","phase":"Phase 2","brief_title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03914300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"ae4bc21b-56da-43de-9d91-fda963c4eb35","acronym":"","url":"https://clinicaltrials.gov/study/NCT05541380","created_at":"2022-09-15T16:06:07.463Z","updated_at":"2024-07-02T16:35:28.349Z","phase":"","brief_title":"A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)","source_id_and_acronym":"NCT05541380","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-11-22"},{"id":"d6544d5c-22e0-428e-b270-2a60bc0e02bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447183","created_at":"2021-01-18T21:23:59.877Z","updated_at":"2024-07-02T16:35:32.204Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","source_id_and_acronym":"NCT04447183","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e recombinant human thyroid stimulating hormone for injection (rhTSH)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-23"},{"id":"2e2eca56-d2c6-4ba6-84f4-22cb6d82234a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02393690","created_at":"2021-01-18T11:24:58.815Z","updated_at":"2024-07-02T16:35:56.531Z","phase":"Phase 2","brief_title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02393690","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/04/2015","start_date":" 05/04/2015","primary_txt":" Primary completion: 07/17/2020","primary_completion_date":" 07/17/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-02"},{"id":"0dff7f04-3f58-49c6-8eb8-ea8e8e1ba046","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453799","created_at":"2022-07-12T10:54:40.764Z","updated_at":"2024-07-02T16:36:04.939Z","phase":"Phase 2","brief_title":"Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT05453799","lead_sponsor":"Northwestern University","biomarkers":" BRAF • CD4","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2022-08-24"},{"id":"c0fb26e4-588f-4ea3-80da-f8b88b7324e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02702388","created_at":"2021-07-05T16:52:02.815Z","updated_at":"2025-02-25T16:04:25.407Z","phase":"Phase 2","brief_title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","source_id_and_acronym":"NCT02702388","lead_sponsor":"Eisai Inc.","biomarkers":" FGF23 • TG","pipe":"","alterations":" ","tags":["FGF23 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 241","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2021-11-24"},{"id":"868f20e2-cb59-435e-8f2a-4edb23b8dd9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01208051","created_at":"2021-01-18T04:50:33.670Z","updated_at":"2024-07-02T16:36:27.878Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01208051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAS • TG","pipe":" | ","alterations":" RAS mutation","tags":["BRAF • RAS • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 09/09/2010","start_date":" 09/09/2010","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2021-07-15"},{"id":"beafe807-5a78-4bd5-ba5e-40d252bfd50e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554680","created_at":"2021-01-18T21:46:28.506Z","updated_at":"2024-07-02T16:36:33.733Z","phase":"Phase 2","brief_title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF \u0026 MEK Blockade for Re-differentiation Therapy","source_id_and_acronym":"NCT04554680","lead_sponsor":"National University Hospital, Singapore","biomarkers":" TG","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2021-03-05"},{"id":"c0574e54-21c3-41b5-84d1-fbcc20890755","acronym":"","url":"https://clinicaltrials.gov/study/NCT01811212","created_at":"2021-01-18T08:02:03.039Z","updated_at":"2024-07-02T16:37:11.852Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer","source_id_and_acronym":"NCT01811212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • TG","pipe":"","alterations":" ","tags":["BRAF • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/08/2013","start_date":" 05/08/2013","primary_txt":" Primary completion: 07/13/2015","primary_completion_date":" 07/13/2015","study_txt":" Completion: 10/09/2017","study_completion_date":" 10/09/2017","last_update_posted":"2018-04-03"}]